AIM: To evaluate the relative efficacy and safety of aflibercept for treatment of diabetic macular oedema(DMO).METHODS: A comprehensive search in MEDLINE, CENTRAL and EMBASE was undertaken for randomized controlled tr...AIM: To evaluate the relative efficacy and safety of aflibercept for treatment of diabetic macular oedema(DMO).METHODS: A comprehensive search in MEDLINE, CENTRAL and EMBASE was undertaken for randomized controlled trials(RCTs) comparing intravitreal antivascular endothelial growth factor(anti-VEGF) versus another treatment. Primary outcome measures were proportion of patients with at least 15 letters of gain or loss on a log MAR visual acuity chart, and change in best corrected visual acuity(BCVA) and central macular thickness(CMT) from baseline. Safety outcomes were rates of death, thromboembolic events and any systemic or ocular serious adverse events. The final search was performed on November 2017.RESULTS: Four RCTs were included. Only one trial compared efficacy and safety of aflibercept with bevacizumab and ranibizumab over 1 or 2 y. Three trials were included for Meta-analysis comprising 661 patients(331 in the aflibercept, and 330 in the photocoagulation group). Aflibercept was more efficacious compared to photocoagulation in the proportion of patients with at least 15 letters of improvement and worsening, and in improvement of BCVA and reduction in CMT at 1 or 2 y. The safety estimates at 1 or 2 y did not differ statistically.CONCLUSION: Aflibercept offers superior benefits over photocoagulation in improving and preserving vision, with no differences in safety. Further comparative effectiveness trials between aflibercept and other anti-VEGF agents will aid ophthalmologists in treatment decisions.展开更多
基金Supported by the University of Sydney,Sydney,Australia
文摘AIM: To evaluate the relative efficacy and safety of aflibercept for treatment of diabetic macular oedema(DMO).METHODS: A comprehensive search in MEDLINE, CENTRAL and EMBASE was undertaken for randomized controlled trials(RCTs) comparing intravitreal antivascular endothelial growth factor(anti-VEGF) versus another treatment. Primary outcome measures were proportion of patients with at least 15 letters of gain or loss on a log MAR visual acuity chart, and change in best corrected visual acuity(BCVA) and central macular thickness(CMT) from baseline. Safety outcomes were rates of death, thromboembolic events and any systemic or ocular serious adverse events. The final search was performed on November 2017.RESULTS: Four RCTs were included. Only one trial compared efficacy and safety of aflibercept with bevacizumab and ranibizumab over 1 or 2 y. Three trials were included for Meta-analysis comprising 661 patients(331 in the aflibercept, and 330 in the photocoagulation group). Aflibercept was more efficacious compared to photocoagulation in the proportion of patients with at least 15 letters of improvement and worsening, and in improvement of BCVA and reduction in CMT at 1 or 2 y. The safety estimates at 1 or 2 y did not differ statistically.CONCLUSION: Aflibercept offers superior benefits over photocoagulation in improving and preserving vision, with no differences in safety. Further comparative effectiveness trials between aflibercept and other anti-VEGF agents will aid ophthalmologists in treatment decisions.
